Investment and expertise
for promising, early-stage
Scottish technology and
life science companies.
WHAT WE DO
We are a prominent
business angel syndicate,
which has been at the
forefront of early stage
investing in Scotland for
more than two decades.
SEE OUR MEMBER BENEFITS
We invest in companies
from the technology,
software and life sciences
sectors – three markets in
which Scotland produces
a wealth of talent.
SEE IF YOU MEET THE CRITERIA

Originally formed in 1992 and based in Edinburgh, Archangels is a prominent business angel syndicate which has been at the forefront of early stage investing in Scotland for more than a quarter of a century.

Latest News

Sorting:
  • Bloxx acquired by Akamai Technologies, Inc.

    Livingston-based Bloxx, the provider of real-time Internet and email filtering solutions, has been sold by its shareholders – including Archangel Investors and Scottish Investment Bank – to US-based Akamai Technologies, Inc. Bloxx was established in 1999 and has grown to become one of the world’s leading providers of web and email filtering for medium sized […]

  • Archangels Impact Evaluation Report

    We are delighted that Deputy First Minister John Swinney, MSP will be joining us at the Strathclyde University Technology and Innovation Centre in Glasgow to launch the findings of a study into the economic impact of Archangels on the Scottish Economy over the last 22 years. Click on link below to read the report Archangels: […]

  • Dundee-based CXR Biosciences Joins Concept Life Sciences Group

    CXR Biosciences Limited, (“CXR”) the Dundee-based investigative and exploratory toxicology business, has been sold by its shareholders – including Archangel Investors and Scottish Investment Bank – to UK-based Concept Life Sciences, the growing life sciences, scientific laboratory and consultancy group. CXR is a leading investigative toxicology business. Its in-house expertise assists international life sciences companies […]

  • MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections

    MGB Biopharma is at the forefront of efforts to tackle the global rise in antibiotic resistant infections Glasgow, Scotland, 21st July 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have […]

  • MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections

    MGB Biopharma is at the forefront of efforts to tackle the global rise in antibiotic resistant infections Glasgow, Scotland, 21st July 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have […]

  • NCTech on the News!

    Click on the link to see Neil Tocher from NCTech talking about their new Iris360 camera and a new project with Google Street View. NCTech on STV. For more information check out their Facebook page NCTech Facebook

Company portfolio

  • Archangel Investors Ltd
  • Archangel Investors Ltd
  • Archangel Investors Ltd
  • RT @Blackford: Planning to attend AIMed Radiology virtual conference on November 5? Then tune in at 3:10 PM! Blackford CEO Ben Panter will…
    Archangel Investors Ltd about 1 days ago
  • RT @speechgraphics: Speech Graphics are looking for a Speech Data Engineer to join our Data Team! This is your chance to join an exciting…
    Archangel Investors Ltd about 3 days ago
  • RT @AngelNews: @hear_diags, a revolutionary hearing test, has secured a £715,000 investment from @ArchangelInvest to enable its hearing tes…
    Archangel Investors Ltd about 10 days ago

See our ‘Impact evaluation of activities report’ by the Hunter Centre for Entrepreneurship at The University of Strathclyde.